Janux Therapeutics (JANX) Receivables (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Receivables data on file, last reported at $42.5 million in Q1 2026.

• Receivables for Q1 2026 came in at $42.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $42.5 million (changed N/A YoY), and the FY2025 annual result was $6.4 million, changed N/A from the prior year.
• Receivables rose to $42.5 million in Q1 2026 per JANX's latest filing, from $6.4 million in the prior quarter.
• Over five years, Receivables peaked at $42.5 million in Q1 2026 and troughed at $500000.0 in Q3 2022.
• A 5-year average of $9.8 million and a median of $4.4 million in 2024 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 450.62% in 2024 and fell as far as 450.62% in 2024.
• A 5-year view of Receivables shows it stood at $500000.0 in 2022, then soared by 332.2% to $2.2 million in 2023, then soared by 457.89% to $12.1 million in 2024, then tumbled by 46.68% to $6.4 million in 2025, then jumped by 560.59% to $42.5 million in 2026.
• Business Quant data shows JANX's Receivables at $42.5 million in Q1 2026, $6.4 million in Q4 2025, and $12.1 million in Q2 2024.